GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Kidney and Dialysis, 2022 Diabetic kidney disease (DKD) represents an important diabetes (DM) complication associated with significant impacts on morbidity, mortality, and quality of life. Recent evidence from cardiovascular and kidney outcome trials has dramatically impacted the
Joshua J. Neumiller +2 more
doaj +1 more source
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]
Endocrinology and MetabolismObesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska +2 more
doaj +1 more source
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor [PDF]
, 2022 Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists.
Münzel, Thomas +5 more
core +1 more source
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Frontiers in Neuroscience, 2022 Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness.
Zaynab Ahmad Mouhammad +11 more
doaj +1 more source
Adverse Effects of GLP-1 Receptor Agonists [PDF]
The Review of Diabetic Studies, 2014 Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively new class of drugs may be associated with certain adverse effects.
Theodosios D, Filippatos +2 more
openaire +2 more sources
GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events. [PDF]
, 2022 Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) lower plasma glucose through effects on insulin and glucagon secretion and by decelerating gastric emptying.
Muka, Taulant +6 more
core +2 more sources
Development of a Cost-Effective ELISA-Based cAMP Assay for Evaluating Small-Molecule GLP-1 Receptor Agonists [PDF]
BIO Web of ConferencesBackground: Glucagon-like peptide-1 receptor agonists (GLP-lRAs) play an important role in the treatment of metabolic diseases. Evaluation of their biological activity is commonly performed by measuring intracellular cyclic adenosine monophosphate (cAMP)
Mei Xuejiao, Lu Dingqiang
doaj +1 more source
GLP-1 Receptor Agonists and Kidney Protection
Medicina, 2019 Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR).
Eulalia Greco +5 more
openaire +3 more sources
Glucagon-like peptide-1 receptor imaging for localization of insulinomas [PDF]
, 2009 The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be ...
Clerici, Thomas +21 more
core +3 more sources
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source